Drug Profile
PL 601
Alternative Names: PL601Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Polyrizon
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Atopic dermatitis in Israel (Topical)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Atopic-dermatitis in Israel (Topical, Gel)